The Strategic Guide to the CMS RAPID Coverage Pathway for MedTech Startups

CMS and FDA's Coordinated Leap in MedTech Reimbursement

For over two decades, the "reimbursement gap" has been the single most predictable bottleneck in US medical device commercialization. While the Food and Drug Administration (FDA) evaluates a device based on safety and effectiveness, the Centers for Medicare & Medicaid Services (CMS) evaluates whether it is "reasonable and necessary" for the Medicare population. This structural misalignment has historically forced medical device innovators into a sequential evidence generation strategy, leading to an average delay of twelve months—and frequently up to several years—between obtaining an FDA clearance or approval and securing a National Coverage Determination (NCD).

This article is part of Mediclever’s medical device reimbursement resources.

Last updated: June 1, 2026

On April 23, 2026, CMS and the FDA jointly announced a major structural shift designed to compress this timeline to as little as two months: the Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway.

By integrating CMS clinical evidence expectations directly into the pre-market phase, the RAPID pathway represents a major evolution in how the federal government approaches MedTech innovation. For manufacturers of breakthrough technologies, understanding the operational mechanics, strict eligibility criteria, and strategic tradeoffs of this new framework is critical to maximizing asset value and ensuring immediate market access upon commercial launch.

The Architecture of the RAPID Pathway

The core objective of the RAPID pathway is to eliminate duplicative clinical trial requirements by establishing early, simultaneous alignment between the manufacturer, the FDA, and CMS. Instead of treating regulatory authorization and reimbursement as distinct hurdles, the program brings CMS to the table while a device’s pivotal clinical trials are still being designed.

Under standard historical procedures, the NCD process could only be initiated after FDA authorization, consuming nine to twelve months under optimal conditions. RAPID systematically restructures this timeline through two main mechanisms:

Coordinated Evidence Generation: CMS experts actively participate in the early, frequent engagements that occur under the FDA Breakthrough Devices Program. This allows innovators to bake CMS's specific, patient-outcome-based metrics directly into their pre-market clinical protocols.
Synchronized Coverage Issuance: If a manufacturer successfully executes the agreed-upon evidence generation strategy, CMS will issue its proposed NCD on the exact same day the FDA grants market authorization. Following a standard 30-day public comment window, CMS targets a final coverage decision within 60 to 90 days of launch.

Working with an experienced medical device reimbursement consultant can help you synchronize the company's clinical development plan to address both the FDA's and CMS's requirements. This forms the bedrock of our specialized approach to Medical Device Reimbursement Planning.

Eligibility Criteria and Program Scale

Unlike previous, highly restricted pilot programs, RAPID is built to function at a commercial scale, with agency officials estimating an initial capacity of 40 to 60 eligible devices. To qualify for the pathway, a technology must meet explicit regulatory and clinical benchmarks:

Criteria	Requirements & Parameters
Regulatory Status	Must possess formal FDA Breakthrough Device designation.
Device Classification	Available to all Class III devices. Class II devices are eligible only if they actively participate in the FDA’s Total Product Life Cycle Advisory Program (TAP).
Clinical Value	Must explicitly address an unmet medical need specifically within the Medicare beneficiary population.
Trial Framework	Must be the subject of an Investigational Device Exemption (IDE) study that actively enrolls Medicare beneficiaries and evaluates clinical health outcomes jointly agreed upon by both the FDA and CMS.

Operational Note on TAP Alignment: The requirement for Class II breakthrough devices to be enrolled in the FDA TAP program underscores the reliance on structured, early-stage advisory channels. Currently, TAP covers ophthalmic, cardiovascular, neurological, physical medicine, orthopedic, and radiologic health devices, with further clinical specialty expansions slated for later in 2026.

Strategic Considerations and Evidentiary Tradeoffs

While the prospect of securing national Medicare coverage within 60 to 90 days of an FDA launch offers a massive commercial inflection point, participation in RAPID is voluntary and introduces distinct operational pressures. Market access executives must carefully weigh the following strategic realities before enrolling:

1. Heightened Evidentiary Bars

The FDA’s standard for market entry focuses heavily on safety and functional performance metrics. CMS, conversely, requires clear evidence of improved clinical health outcomes for the Medicare population. Consequently, an IDE trial designed to satisfy both agencies under RAPID will almost certainly demand larger sample sizes, more robust demographic sub-stratification (ensuring adequate representation of older adults or disabled populations), longer follow-up horizons, and harder clinical endpoints. Manufacturers must evaluate whether the capital required to run an expanded trial outweighs the long-term cost of a multi-year coverage lag post-launch.

2. Coverage with Evidence Development (CED) Risk

CMS retains the right to implement a flexible approach to coverage under RAPID. If pre-market data shows immense promise but lacks long-term definitive clarity, CMS may issue an NCD that conditions ongoing reimbursement upon further data collection. This means a device could launch with immediate coverage but remain bound to rigorous post-market approval studies or continuous registry reporting to maintain its reimbursement status.

3. Shifting Market Access Dynamics

Concurrently, CMS has proposed structural changes to other reimbursement mechanisms, such as proposing to phase out the specialized New Technology Add-On Payment (NTAP) pathway rules for Breakthrough Devices in the inpatient setting (forcing them to meet the standard "substantial clinical improvement" criteria applied to non-breakthrough assets). This broader shifting regulatory climate elevates the importance of the RAPID pathway, making early, integrated evidence generation a primary vehicle for achieving predictable, high-value US market entry.

The Bottom Line

The RAPID coverage pathway effectively ends the era of sequential clinical strategy. For MedTech executives, investors, and clinical trial designers, reimbursement can no longer be treated as a secondary, post-regulatory workstream. Success under this synchronized model requires integrating macroeconomic payer demands directly into early-stage clinical trial designs, transforming reimbursement from a commercial afterthought into a primary driver of clinical development.

More on medical device reimbursement in the USA

For a broader overview of the market, explore our comprehensive guide to USA Medical Device Reimbursement.

Frequently Asked Questions About the CMS RAPID Pathway

What is the CMS RAPID coverage pathway?

The Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway is a joint CMS-FDA initiative designed to accelerate national Medicare coverage for eligible breakthrough medical devices to within 2 to 3 months post-FDA authorization.

Which medical devices are eligible for the RAPID pathway?

Eligible technologies must hold formal FDA Breakthrough Device designation, address an unmet need in the Medicare population, and utilize an IDE trial that tracks clinical outcomes agreed upon by both CMS and FDA. Class III devices qualify directly, while Class II devices must also participate in the FDA's TAP program.

How does RAPID shorten the US reimbursement timeline?

By integrating CMS evidence review directly into the pre-market trial planning phase, CMS can issue a proposed National Coverage Determination (NCD) on the exact same day the FDA grants market authorization, saving up to a year or more of sequential waiting.

What happens to the TCET pathway now that RAPID is introduced?

CMS has paused the Transitional Coverage for Emerging Technologies (TCET) pathway for new candidates to focus agency resources on the successful implementation and wider operational scale of the RAPID pathway.